摘要
IgA肾病(IgA nephropathy, IgAN)是世界上常见的原发性肾小球疾病,也是导致终末期肾病的主要原因之一,大约有25%~30%的患者在发病后20~25年内发生肾衰竭。IgAN的特征是糖基化异常的IgA1免疫复合物在肾小球系膜区沉积并引起一系列炎症反应导致肾脏损伤。研究表明,Janus激酶/信号转导和转录激活因子(JAK/STAT)信号通路与IgAN的发病、病情进展及致病基因等存在密切联系,阻断该信号通路有望在IgAN的治疗中发挥作用。本文对近年来JAK-STAT信号通路与IgAN的关系研究进行综述。
As a common primary glomerular disease, IgA nephropathy(IgAN) is also one of major causes of end-stage renal disease.And 25% to 30% of any cohort developed kidney failure within 20 to 25 years of presentation.IgAN is characterized by a deposition of glycosylated IgA1 immune complexes in glomerular mesangial area and a cascade of inflammatory reactions leading to renal injury.Numerous studies have demonstrated a close relationship between Janus kinase(JAK)/signal transducers or activators of transcription(STAT) signal pathway and the pathogenesis, progression and pathogenic genes of IgAN.Blocking this signal pathway may contribute to potential treatment of IgAN.This review examined the relationship between JAK/STAT signal pathway and IgA nephropathy in recent years.
作者
慈鑫
郑倩
栾如梅
卢雪红
Ci Xin;Zheng Qian;Luan Ru-mei;Lu Xue-hong(Department of Nephrology,Second Hospital,Jilin University,Changchun 130041,China)
出处
《临床肾脏病杂志》
2021年第12期1048-1051,共4页
Journal Of Clinical Nephrology
基金
吉林省卫生与健康技术创新项目(2020J037)。
关键词
JANUS激酶
信号转导和转录激活因子
IGA肾病
治疗
Janus Kinase
Signal transducer and activator of transcription
IgA nephropathy
Treatment prospects
